190 related articles for article (PubMed ID: 20587664)
21. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
22. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
23. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
24. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.
Emlet DR; Gupta P; Holgado-Madruga M; Del Vecchio CA; Mitra SS; Han SY; Li G; Jensen KC; Vogel H; Xu LW; Skirboll SS; Wong AJ
Cancer Res; 2014 Feb; 74(4):1238-49. PubMed ID: 24366881
[TBL] [Abstract][Full Text] [Related]
25. RNA aptamers targeting cancer stem cell marker CD133.
Shigdar S; Qiao L; Zhou SF; Xiang D; Wang T; Li Y; Lim LY; Kong L; Li L; Duan W
Cancer Lett; 2013 Mar; 330(1):84-95. PubMed ID: 23196060
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
27. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
28. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
29. Targeting cancer stem cells through L1CAM suppresses glioma growth.
Bao S; Wu Q; Li Z; Sathornsumetee S; Wang H; McLendon RE; Hjelmeland AB; Rich JN
Cancer Res; 2008 Aug; 68(15):6043-8. PubMed ID: 18676824
[TBL] [Abstract][Full Text] [Related]
30. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
31. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.
Chen R; Nishimura MC; Bumbaca SM; Kharbanda S; Forrest WF; Kasman IM; Greve JM; Soriano RH; Gilmour LL; Rivers CS; Modrusan Z; Nacu S; Guerrero S; Edgar KA; Wallin JJ; Lamszus K; Westphal M; Heim S; James CD; VandenBerg SR; Costello JF; Moorefield S; Cowdrey CJ; Prados M; Phillips HS
Cancer Cell; 2010 Apr; 17(4):362-75. PubMed ID: 20385361
[TBL] [Abstract][Full Text] [Related]
32. BMI1 sustains human glioblastoma multiforme stem cell renewal.
Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
[TBL] [Abstract][Full Text] [Related]
33. A2B5 cells from human glioblastoma have cancer stem cell properties.
Tchoghandjian A; Baeza N; Colin C; Cayre M; Metellus P; Beclin C; Ouafik L; Figarella-Branger D
Brain Pathol; 2010 Jan; 20(1):211-21. PubMed ID: 19243384
[TBL] [Abstract][Full Text] [Related]
34. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines.
Qiang L; Yang Y; Ma YJ; Chen FH; Zhang LB; Liu W; Qi Q; Lu N; Tao L; Wang XT; You QD; Guo QL
Cancer Lett; 2009 Jun; 279(1):13-21. PubMed ID: 19232461
[TBL] [Abstract][Full Text] [Related]
35. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
36. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
37. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
38. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
Osmond TL; Broadley KW; McConnell MJ
Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
[TBL] [Abstract][Full Text] [Related]
40. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
